Latest From Genfit SA
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
Atypical histological findings from a Phase IIb NASH study lead CymaBay to terminate mid-stage studies in NASH and PSC and place a Phase III PBC trial on hold.
Other NASH registration trails have targeted fibrosis, but Galectin's mostly-resolved discussions with US FDA will allow the belapectin program to focus of signs and symptoms of the disease.
Galectin faces a dual challenge - do its planned trial well and trust that the study design will lead the galectin-3 inhibitor belapectin to a niche position in NASH.
Drug Discovery Tools
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Hepatic (Liver)
- Immune Disorders
- Metabolic Disorders
- Western Europe
- Parent & Subsidiaries
- Genfit SA
- Senior Management
Jean-Francois Mouney, Chmn. & CEO
Nathalie Huitorel, EVP, CFO & Chief Administrative Officer
Dean Hum, PhD, COO
Carol L Addy, MD, CMO
- Contact Info
Phone: (33) 3 20 16 40 00
885 Ave. Eugene Avinee
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.